**Core tip:** *BRIP1* gene alterations are uncommon in gastrointestinal cancers. Mutations frequently occur in hypermutated carcinomas and co-occur with other homologous recombination genes mutations. Despite their rarity, BRIP1 defects may present an opportunity for therapeutic interventions similar to other homologous recombination defects.

INTRODUCTION
============

BRIP1 \[BRCA1 interacting protein C-terminal helicase 1, alternatively called FANCJ, Fanconi Anemia (FA) complementation group J or BACH1, BRCA1 Associated C-terminal Helicase 1\] is a 1249 amino-acid protein with helicase function that participates in DNA homeostasis. The gene (Gene ID: 83990) is located at human chromosome 17q23.2 and consists of 20 exons, 19 of which (exons 2 to 20) are coding. BRIP1 protein plays a role in DNA repair through homologous recombination (HR) and interacts with BRCA1\[[@B1]\]. BRIP1 has also BRCA1 independent effects in DNA repair that depend on the helicase activity\[[@B2]\]. Besides BRCA1, BRIP1 interacts with mismatch repair (MMR) protein MLH1 and promotes signaling for apoptosis at sites with O^6^-methylated guanine adducts\[[@B3]\]. BRIP1 mutant cells that lose the ability for MLH1 interaction survive better when methyl-guanine methyltransferase MGMT is functional as MGMT has more time to process the defective site. BRIP1-MLH1 interaction may be as important as the interaction with BRCA1 in signaling from inter-strand cross-links and underlines the role of BRIP1 as a key player at the cross-roads of DNA repair though the FA pathway and the MMR as well as the HR pathway\[[@B4]\]. Besides inter-strand cross-links, a role of BRIP1 in repairing other abnormal DNA structures, such as G-quadruplex structures and hairpins, arising during DNA replication, under replication stress, has been recently established\[[@B5]\].

*BRIP1* has been implicated in hereditary ovarian cancers that lack *BRCA1* or *BRCA2* mutations\[[@B6]\]. Up to 0.6%-0.9% of ovarian cancers may carry pathogenic variants in BRIP1, although the percentage may vary in different populations\[[@B7]\]. A role of *BRIP1* in hereditary breast cancer has also been proposed but is debated\[[@B8],[@B9]\]. Similarly, rare cases of prostate cancer with *BRIP1* mutations reminiscent of prostate cancer in BRCA2 families have been reported\[[@B10],[@B11]\]. Leukemia predisposition is part of FA and has been described with BRIP1 hereditary mutations, in common with other FA complementation group gene mutations\[[@B12]\]. The implication of BRIP1 as a tumor suppressor in other hereditary cancers or in sporadic cancers is even less clear.

This paper investigates the role of BRIP1 defects in gastrointestinal (GI) cancers exploring publicly available genomic data from The Cancer Genome Atlas (TCGA) available in the cBioportal of cancer genomics platform.

MATERIALS AND METHODS
=====================

Studies performed by TCGA consortium (PanCancer Atlas) that were evaluated in the current investigation included esophageal adenocarcinoma (containing 182 samples), gastric adenocarcinoma (containing 440 samples), pancreatic adenocarcinoma (containing 184 samples), colorectal cancer (containing 594 samples), cholangio-carcinoma (with 36 samples)\[[@B13]-[@B17]\]. Analyses were performed in the cBioCancer Genomics Portal (cBioportal, <http://www.cbioportal.org>) platform\[[@B18],[@B19]\]. cBioportal contains 172 non-overlapping genomic studies published by TCGA and by other investigators worldwide and empowers interrogation of each study or group of studies for genetic lesions in any gene of interest, in a user-friendly manner. The five studies selected for the current investigation cover the most updated available TCGA results of the most common GI cancers.

cBioportal currently provides assessment of the functional implications of mutations of interest using the mutation assessor and other relevant tools. The mutation assessor (mutationassessor.org) uses a multiple sequence alignment algorithm to assign a prediction score of functional significance to each mutation\[[@B20]\]. Data from the mutation assessor as reported in cBioportal were used for evaluation of putative functional repercussions of *BRIP1* mutations and other mutations of interest. Data from the OncoKB database, a precision oncology database annotating the biologic and oncogenic significance of somatic cancer mutations were incorporated in the functional assessment of discussed mutations\[[@B21]\].

Survival of gastric cancer patients with high expression of *BRIP1* mRNA *vs* those with low *BRIP1* mRNA expression was compared using the online tool Kaplan Meier Plotter (kmplot.com)\[[@B22]\]. This online tool currently does not include other GI cancers.

Investigation of BRIP1 promoters was performed using the EPD database (<http://epd.epfl.ch>) and putative transcription factor binding sites were identified using the JASPAR CORE 2018 vertebrate database\[[@B23]\].

For further analyses that could not be performed directly in cBioportal, the list of genes and relevant mutated or amplified samples from each study of interest was transferred to an Excel sheet (Microsoft Corp., Redmond, WA) for performance of required calculations. Categorical and continuous data were compared with the Fisher's exact test and the *t* test respectively. Correlations were explored with the Pearson correlation coefficient. All statistical comparisons were considered significant if *P* \< 0.05. Correction for multiple comparisons was performed using the Benjamini-Hochberg false discovery rate correction procedure.

RESULTS
=======

The frequency of *BRIP1* mutations was low in the GI cancers examined. Among the 1436 samples included in the 5 interrogated studies, 30 samples (2.1%) had one or more *BRIP1* mutations. There was a total of 38 *BRIP1* mutations in these 30 samples. The distribution of mutations in the exons of *BRIP1* is shown in Figure [1](#F1){ref-type="fig"}. Six of 38 mutations (15.8%) were listed as likely oncogenic in the OncoKB database (Table [1](#T1){ref-type="table"}). These six mutations occur in different aminoacid residues in different exons besides a mutation at aminoacid I504 recurring in two samples and resulting in frame shift and protein truncation shortly thereafter. The remaining four likely oncogenic *BRIP1* mutations are nonsense mutations. The incidence of mutated *BRIP1* samples in each of the 5 studies was as follows: esophageal cancer 2.2% (4 of 182 cases), gastric cancer 1.6% (7 of 440 cases), pancreatic cancer 0.5% (1 of 184 cases), no mutations observed in the 36 samples of the cholangiocarcinoma study, colorectal cancer 3% (18 of 594 cases) (Figure [2](#F2){ref-type="fig"}).

###### 

Likely oncogenic *BRIP1* mutations in gastrointestinal cancers according to the OncoKB database

  **Sample ID**     **Cancer type**             **Protein change**   **Mutation type**    **Copy number**   **Allele frequency**   **Number of mutations**   **Exon**
  ----------------- --------------------------- -------------------- -------------------- ----------------- ---------------------- ------------------------- ----------
  TCGA-A6-3807-01   Colon adenocarcinoma        S1117\*              Nonsense_muta-tion   Diploid           0.21                   90                        20
  TCGA-DT-5265-01   Rectal adenocarcinoma       Q227\*               Nonsense_muta-tion   Shallow del       0.59                   81                        7
  TCGA-AA-3496-01   Colon adenocarcinoma        I504Nfs\*7           Frame_Shift_Ins      Gain              0.43                   145                       11
  TCGA-AZ-4315-01   Colon adenocarcinoma        E357\*               Nonsense_muta-tion   Diploid           0.32                   6317                      8
  TCGA-L5-A4OE-01   Esophageal adenocarcinoma   Q126\*               Nonsense_muta-tion   Gain              0.35                   267                       4
  TCGA-CG-5721-01   Gastric adenocarcinoma      I504Sfs\*22          Frame_Shift_Del      Diploid           0.22                   3725                      11

The column "Number of mutations" presents the total number of mutations in the respective sample. Ins: Insertion; Del: Deletion.

![Number of mutations in each exon of *BRIP1*. The total number of mutations in the five gastrointestinal adenocarcinomas examined were 38 in 30 samples.](WJG-26-1197-g001){#F1}

![Percentage of *BRIP1* mutations in the five gastrointestinal adenocarcinomas.](WJG-26-1197-g002){#F2}

The total number of mutations in *BRIP1* mutant samples varied widely ranging between 78 and 11438. The mean and median number of mutations were high (2993.2 and 1747.5 respectively) and 17 of 30 samples with *BRIP1* mutations (56.7%) had more than 1000 mutations each. Such a heavy mutation burden is usually observed in cancers with microsatellite instability (MSI) due to mutations in genes that encode for MMR proteins that include *MSH2*, *MSH6*, *MLH1* and *PMS2* or alternatively in cancers with mutations in polymerases ε and δ1 (POLE and POLD1 respectively). Indeed, 18 of the 30 *BRIP1* mutated samples (60%) contained one or more co-occurring mutations in one of these six genes. The mean number of mutations in the 18 samples with at least one co-occurring MSI/*POLE*/*POLD1* mutations was 4813 while the mean number of mutations in the 12 samples without any co-occurring MSI/*POLE*/*POLD1* mutations was 262.7. Seventeen of the 18 samples with at least one MSI/ *POLE*/*POLD1* mutation had over 1000 total mutations, while none of the 12 samples with *BRIP1* mutations but no MSI/*POLE*/*POLD1* mutation had over 1000 total mutations. Two samples, including the single sample with a *BRIP1* mutation in the pancreatic cancer study that contained the higher number of total mutations, an extraordinary 11438, contained mutations in all six MSI/*POLE*/*POLD1* genes. The percentage of mutations in each of the six genes in *BRIP1*-mutated samples was significantly higher than this percentage in the samples of the 5 studies without *BRIP1* mutations (Figure [3](#F3){ref-type="fig"}). *POLE* mutations were observed in 14 of the 30 *BRIP1* mutant samples (46.7%). Nine of these *POLE* mutations were deemed likely oncogenic by the OncoKB database, including 4 samples with the known *POLE* hotspot mutations V411L and 2 samples with P286R/L hotspot mutations. The 5 studies contained 74 samples (5.1%) with mutations in *POLE* and among those 5 and 4 were the hotspot mutations V411L and P286R/L. Thus, a significant proportion of these characterized deleterious mutations co-occur with *BRIP1* mutations. Overall these data suggest that *BRIP1* mutations do not cause increased tumor burden but are commonly observed in samples with underlying MSI/*POLE*/*POLD1* mutations and thus a substantial subset of GI cancers with somatically mutated *BRIP1* have a high tumor mutation burden.

![Mutation frequency of *MSI* and *POLE*/*POLD1* genes in gastrointestinal cancers with BRIP1 abnormalities (altered group) and without BRIP1 abnormalities (unaltered group). Comparison of the altered and unaltered group is statistically significant for all six genes.](WJG-26-1197-g003){#F3}

Among the six samples with likely oncogenic *BRIP1* mutations four samples had lower total mutation number (between 81 and 267, Table [1](#T1){ref-type="table"}) and three of them had no concomitant MSI/*POLE*/*POLD1* mutations while the fourth, a colorectal cancer sample with a *BRIP1* frameshift mutation at I507 had a mutation in *MLH1* at L697. These data suggest that likely oncogenic *BRIP1* mutations could contribute to cancer pathogenesis without producing hypermutability. Other *BRIP1* mutations with unknown significance may be passengers in hyper-mutated cancers.

In colorectal cancer two thirds of BRIP1-mutated samples (12 of 18) contained also mutations in one or more of the commonly mutated genes of the KRAS/BRAF pathway (KRAS/NRAS/BRAF/PTEN/PIK3CA). There was a significant co-occurrence of *BRIP1* mutations with mutations in *BRAF* and *PTEN*. However, all 12 samples with *BRIP1* mutations co-occurring with the five genes of the KRAS/BRAF pathway were hypermutated and contained mutations in either *POLE* or *POLD1* or both. Thus, the presence of *BRIP1* mutations in samples with mutations in genes of the KRAS/BRAF pathway may be co-incidental due to the high mutations burden of hypermutated cancers.

Proteins directly interacting with BRIP1 during the DNA repair function include BRCA1 and MLH1. Thus, mutations of these proteins, especially in their BRIP1-interacting domains, or deletions of BRCA1 and MLH1 even in the absence of BRIP1 lesions per se may result in interference with normal function of BRIP1. BRCA1 interacts with BRIP1 through its BRCT domain (aminoacids 1662-1723 and 1757-1842). Mutations in BRCT domain of BRCA1 were observed in only one sample of the total 1436 samples in the 5 studies of GI cancers. Deletions of BRCA1 were also rare, observed in 3 samples. MLH1 interacts with BRIP1 through its carboxyterminal domain (aminoacids 478-744). Mutations in this part of MLH1 are rare, occurring in 10 samples among the 1436 total samples of the 5 GI cancers studies. Deletion of MLH1 occurred in a single sample.

Several other genes of the FA pathway were found to have low mutation frequencies in the 5 studies examined. *BRCA2* was the only gene that had a mutation percentage above 3%, specifically 6%. Despite low mutation frequencies, mutations in several of these genes such as *BRCA1*, *BRCA2, FANCI*, *FANCD2*, *PALB2*, *FANCC* and *RAD51C* were all observed to statistically significantly co-occur with *BRIP1* mutations (*P* \< 0.001, *Q* \< 0.001).

Comparison of *BRIP1* mutations in GI cancers with *BRIP1* mutations in breast and ovarian cancer disclosed that in breast cancers *BRIP1* mutations are uncommon (10 of 996 samples in the TCGA study of breast cancer, 1%) and contained concomitant MSI/*POLE*/*POLD1* mutations in 3 samples\[[@B24]\]. Similar with GI cancers, mutations of *BRIP1* in breast cancers are widely spread in different exons. In the TCGA study of ovarian cancer the 4 of 5 *BRIP1* mutated samples were observed in the absence of MSI or *POLE*/*POLD1* mutations and 3 of the 4 samples were concentrated in the DEAD-2 domain (aminoacids 248 to 415)\[[@B25]\].

Copy number alterations of *BRIP1* were also uncommon in the studies of the GI cancers examined in this analysis and included 23 *BRIP1* amplified samples (1.6%) and a single deleted sample which occurred in an esophageal cancer. Percentages of amplified samples in the various cancers are presented in Figure [4](#F4){ref-type="fig"}. One thousand four hundred twenty-eight genes were co-amplified significantly more often in *BRIP1* amplified samples than in *BRIP1* non-amplified. Most significant correlations, including the entire list of the top 100 most significantly co-amplified genes were neighboring genes at 17q22-17q24 loci. In gastroesophageal adenocarcinomas, *ERBB2* gene located at 17q12 is commonly amplified in about 15% of cases. Co-amplification of *ERBB2* was observed in 10 of 14 (71.4%) of *BRIP1* amplified gastroesophageal cancer cases (*P* \< 0.001), suggesting that the two genes may be parts of the same amplicon in these cases. As a comparison in breast cancer, where *ERBB2* is also commonly amplified, amplification of the two genes co-occurs with statistical significance (*P* \< 0.001) and 36 of the 82 cases (43.9%) with *BRIP1* amplifications contained concomitant amplification of *ERBB2*.

![Percentage of BRIP1 amplifications in the five gastrointestinal adenocarcinomas.](WJG-26-1197-g004){#F4}

No significant correlations of *BRIP1* amplification with mutations in any gene were found in the GI cancers. For example, co-occurrence of *BRIP1* amplification with the most commonly mutated tumor suppressor *TP53* was observed in 45.8% of *BRIP1* amplified samples while 55.6% of *BRIP1* non-amplified samples had *TP53* mutations (*P* = 0.22). Similarly, co-occurrence of *BRIP1* amplification with the most commonly mutated oncogene *KRAS* was seen in 16.7% of *BRIP1* amplified samples, while 26.6% of *BRIP1* non-amplified samples had *KRAS* mutations (*P* = 0.19).

The promoter region of *BRIP1* gene (from -499 to 100 from Transcription Start Site) contains 5 binding motif sequences for *E2F1* transcription factor at -468, -467, -227, -72 and -71. However, despite this promoter binding potential, *E2F* and *BRIP1* overexpression does not correlate in colorectal cancer (*P* = 0.13), suggesting that E2F1 activity does not lead to over-expression of its potential target BRIP1. *E2F1* was proposed as a part of a panel of genes together with *MYBL2* and *FOXM1* that may predict tumor aneuploidy\[[@B26]\]. Consistent with the lack of increased *BRIP1* expression in tumors with *E2F1* over-expression, aneuploidy scores in *BRIP1* amplified GI tumors were variable, suggesting that, despite the roles of BRIP1 in DNA repair mechanisms, no direct influence of its abundance with ploidy is evident. However, despite lack of clear association with aneuploidy, increased expression of BRIP1 mRNA (above the median) was associated with improved survival in patients with gastric carcinomas compared with patients whose cancers expressed lower *BRIP1* (below the median in the series, Figure [5](#F5){ref-type="fig"}). Similar results were observed when only patients with localized gastric cancers were included in the survival analysis.

![Comparison of overall survival in gastric cancer patients with higher (above the median) and lower (below the median) BRIP1 mRNA expression. Higher BRIP1 mRNA expression was associated with improved overall survival compared with lower BRIP1 mRNA expression in gastric cancer.](WJG-26-1197-g005){#F5}

Another potential transcription factor of interest in the regulation of *BRIP1* is AP1 (a heterodimer of FOS and JUN) because it is often activated downstream of KRAS/BRAF/MAPK pathway, which is often dysregulated in GI cancers. However, no binding sites of AP1 were present in the *BRIP1* promoter.

DISCUSSION
==========

BRIP1 (alternatively called FANCJ or BACH1) is a protein involved in DNA repair and named for both its interaction with BRCA1 and its being a FA pathway member. It belongs to a family of iron-sulfur helicases together with RTEL1, DDX11 and XPD\[[@B27]\]. As a BRCA1 collaborator, BRIP1 participates in DNA repair of inter-strand cross-links through HR downstream of the core FA complex and following ID2 complex (consisting of proteins FANCI and FANCD2) mono-ubiquitination\[[@B28]\]. Other roles of BRIP1 in DNA lesions metabolism have been revealed more recently. BRIP1 participates in protection of DNA from degradation at a stalled fork\[[@B29]\]. In addition, FANCJ directly interacts with MMR protein MLH1 and participates in bridging MMR complexes with the HR machinery for replication restart after inter-strand cross-links repair\[[@B30]\]. Moreover, a direct role of BRIP1 in resolution of G-quadruplex structures and hairpins arising during replication on single strand DNA, especially in microsatellite sites, has been revealed\[[@B31]\]. Consistent with this last role, cells from FANCJ FA patients show MSI, in contrast to other complementation groups\[[@B32]\].

The current study took advantage of published genomic data by the TCGA and the cBioportal platform as well as other online tools to investigate the role of BRIP1 in common GI cancers. Main findings include the low frequency of *BRIP1* defects in GI cancers and a significant association of *BRIP1* mutations with defects of MSI/polymerase ε and δ1 genes and the mutator phenotype. In view of the role of BRIP1 helicase in resolution of abnormal DNA structures often affecting microsatellite sites the association is intriguing and may promote MSI. Consistent with this hypothesis, samples with *BRIP1* mutations in the five studies had a mean of 4813 mutations while the mean number of mutations in the 83 samples of the colorectal TCGA study, for example, with one or more MSI/*POLE*/*POLD1* mutations was 1734. An alternative hypothesis is that samples with more functionally robust MSI/*POLE*/*POLD1* mutations, producing higher total mutation burden, would contain more commonly passenger *BRIP1* mutations.

In pancreatic cancer, where MSI and *POLE*/*POLD1* mutations are rare, *BRIP1* mutations are very rare. Specifically, only one mutation was detected in the TCGA pancreatic cancer study. Another more extensive genomic study that included 359 pancreatic adenocarcinoma samples found no *BRIP1* mutations in any of them\[[@B33]\].

The partner of BRIP1, BRCA1 is an important player in HR and, in this capacity, it needs to interact with chromatin. BRIP1 stabilizes this interaction. In contrast, oncogenic KRAS promotes down-regulation of BRIP1 and BRCA1 dissociation from chromatin leading to cell senescence\[[@B34]\]. Activating mutations in KRAS or other proteins of the pathway are common in GI cancers and thus may affect DNA repair through impairment of the BRCA1/BRIP1 function. This may imply that *KRAS* and *BRCA1*/*BRIP1* lesions would be redundant and mutually exclusive. In this study no such mutual exclusivity between *BRIP1* mutations and *KRAS* mutations was observed and in fact a co-occurrence of *BRIP1* mutations with mutations of other genes of KRAS pathways was present instead. This may be due to the common association of both *BRIP1* and *KRAS* pathway mutations with MSI/hypermutable cancers or alternatively due to lack of functional repercussions for some of these *BRIP1* mutations.

Gastric cancers with BRIP1 mRNA expression above the mean seem to have a better prognosis than counterparts with lower BRIP1 mRNA expression. This may suggest that cancers that up-regulate BRIP1 could have a less aggressive course due to a better ability to repair DNA lesions and possibly decreased genomic lesions accumulation\[[@B35]\].

Despite the fact that the *BRIP1* gene promoter area upstream of its transcription start site contains several putative binding motifs for transcription factor E2F1 and the fact that E2F factors have been confirmed to bind and up-regulate BRIP1 *in vitro*\[[@B36]\], no correlation of the expression of the two genes at the mRNA level in GI cancers was observed in the current interrogation of TCGA studies. This may imply, among other plausible explanations, that other transcription factors are involved in the regulation of BRIP1 obscuring the effect of E2F factors or that increased mRNA expression of E2F does not translate into increased expression of the proteins or increased transcription function. Another candidate transcription factor, AP1, often activated downstream of oncogenic KRAS, was ruled out as a direct regulator of *BRIP1* as it possesses no binding sites in *BRIP1* promoter.

Overall this study suggests that neutralization of BRIP1 as a tumor suppressor seems to play a minor role in GI cancers pathogenesis. However, a contribution as a defect with cumulative influence in cancers with the mutator phenotype is plausible and may be selected by promoting survival in cells with MMR or polymerase mutations, for example if it would contribute to defects in antigen presentation machinery in hypermutated cancers\[[@B37]\]. The association of BRIP1 with the mutator phenotype is intriguing in the current era of immunotherapy of cancer. If a contribution of BRIP1 to an expansion of instability in hypermutated cancers is confirmed, mutations in the gene may become an additional potential predictive marker of response to immunotherapies. In addition, it may suggest potential avenues for combination therapies, for example with immune checkpoint inhibitors and PARP inhibitors. Indeed, such combinations are in development\[[@B38]\].

ARTICLE HIGHLIGHTS
==================

Research background
-------------------

Gastrointestinal (GI) cancers are, as a group, very common and their pathogenesis has been progressively elucidated over the last 30 years. However, the role of genetic lesions in homologous recombination (HR) DNA repair remains less well characterized in these cancers.

Research motivation
-------------------

BRIP1 is a helicase with a role in HR as well as other key functions in DNA metabolism. Its specific role in GI cancers has rarely been reported. Further elucidation of molecular lesions in this gene may pave the way for targeted therapeutic interventions.

Research objectives
-------------------

To analyze molecular defects of helicase BRIP1 (FANCJ) in GIcancers pathogenesis.

Research methods
----------------

GIcancer studies from The Cancer Genome Atlas (TCGA) were analyzed using the cBioportal platform and other precision medicine databases. TCGA studies were interrogated for BRIP1 mutations and copy number alterations. Associations with other key lesions in GIcancers as well as with the total tumor mutation burden in these cancers were analyzed. Additional analyses that could not be performed directly in the cBioportal platform were performed in Excel (Microsoft Corp., Redmond, WA) after transfer of the relevant data. Appropriate statistical tests (the Fisher's exact test and the *t* test respectively) were used for analysis of categorical and continuous data.

Research results
----------------

Molecular lesions in BRIP1 are observed in 3.6% of GI cancers and consisted almost exclusively of mutations and amplifications. Two fifths of all *BRIP1* mutations are considered possibly pathogenic. Most *BRIP1* mutated GI cancers have concomitant mutations in *MMR* genes or one of the replication polymerases, polymerase ε and δ1 genes. No associations were discovered between amplifications of BRIP1 and any mutated genes. BRIP1 amplification commonly co-occurs with ERBB2 amplification, a comparatively common amplification in gastroesophageal cancers.

Research conclusions
--------------------

*BRIP1* gene lesions are not major pathogenic players in GI cancers. Association with microsatellite unstable cancers and ERBB2 amplifications in gastroesophageal cancers is worth noting.

Research perspectives
---------------------

Molecular defects in helicase BRIP1, albeit rare, may provide opportunities for novel therapies in GI cancers. Their association with the mutator phenotype is intriguing in the current era of immunotherapy of cancer. BRIP1 defects may contribute to an expansion of instability in hypermutated cancers. Thus, *BRIP1* mutations could be an additional potential predictive marker of response to immunotherapies. A role of combination therapies, including immunotherapies with targeted therapies active in cancers with HR defects such as PARP inhibitors, in BRIP defective GI cancers is worth exploring.
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